This was the first trial of an IGF-1R treatment in patients with chronic thyroid eye disease to report a significant improvement in diplopia, said Turbin.

ORLANDO — In patients with active or chronic thyroid eye disease, veligrotug improved symptoms of proptosis and diplopia and clinical activity score, according to 15-week results of the ...